Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.5752W HIGH $10.00
Volume
45.83 K
Value Traded
69.95 K
Short % Float
0.15%
-4.51%Week
-19.85%1 Month
-27.34%3 Month
-44.78%6 Month
-95.16%5 Year
-97.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
530.02 M
EPS (TTM)
-0.06
P/E Ratio
-
Ent. Value
516.61 M
Total Shares
200.35 M
Float Shares
39.23 M
Insiders
80.43%
Institutions
0.85%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SSII Catalyst Timeline
Dated clinical, regulatory and corporate events for SS Innovations International Inc.
Past FDA Catalysts and PDUFA Decisions
How SSII actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
SS Innovations International Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every SSII program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sudhir SrivastavaDirector, Officer (Chairman and CEO), 10% Owner | Sell | -33,333 108,520,928 held | $3.00 | 09/04/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SSII
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SSII for Q2 2026. | ||||
SSII Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SSII ranks across every disease it competes in
Competitive Position is a premium feature
See how SSII ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSSII News
SSII▼ -10.9%on this news
SS Innovations Announces Completion of World's Longest-Distance Robotic Telesurgery telesurgery performed by Dr. Sudhir Srivastava utilizing the SSi Mantra surgical robotic system
SS Innovations International, Inc. announced a groundbreaking achievement in telesurgery with the successful completion of the world's longest-distance robotic cardiac surgery, performed by Dr. Sudhir Srivastava from Guyana on a patient in India, spanning approximately 12,500 miles. This procedure utilized the SSi Mantra surgical robotic system and marked a significant milestone in the company's mission to enhance global access to advanced surgical interventions. The achievement coincided with Guyana's 60th independence anniversary and illustrates the potential for technology to bridge geographical barriers in healthcare. The SSi Mantra has established itself as a unique platform for robotic cardiac telesurgery, with regulatory approvals in 14 countries.
Read more →SSIIWe Build Advanced, Affordable and Accessible Surgical Robotic Solutions SS Innovations International, Inc. Company Presentation June 2026 Nasdaq: SSII 2026 SS INNOVATIONS INTERNATIONAL, INC. 2 No Offering of Securities N
SS Innovations International, Inc. is showcasing its commitment to developing advanced, affordable, and accessible surgical robotic solutions. The company highlights its proprietary surgical robotic system, the SSi Mantra 3, and comprehensive suite of surgical instruments. With a strong presence in India and expansion plans into Europe and the US, SS Innovations is capitalizing on a growing total addressable market in surgical robotics. The company reports significant sales growth and has established an impressive installed base across multiple countries.
Read more →SSIISS Innovations Reports First Quarter 2026 Financial Results
SS Innovations International, Inc. reported a significant increase in revenue for Q1 2026, reaching $11.1 million, a 116.8% rise from the previous year. The company also saw a substantial improvement in gross profit and expanded its surgical robotic system installations. Despite a net loss, the company is optimistic about future growth, particularly with recent regulatory approvals and funding from a private placement.
Read more →SSIISS Innovations Demonstrates Long-Distance Telesurgery at Royal Australian College of Surgeons Annual Scientific Congress
SS Innovations International, Inc. successfully completed a landmark long-distance telesurgery utilizing its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console. The procedure was performed by Dr. Mohit Bhandari from Perth, Australia, on a patient located over 4,500 miles away in India during the Royal Australian College of Surgeons Annual Scientific Congress. This achievement highlights the capabilities of the SSi Mantra system, showcasing its potential to transform access to surgical care on a global scale. The company aims to make robotic surgeries more affordable and accessible.
Read more →SSIISS Innovations Surpasses 10,500 Surgeries Performed with the SSi Mantra Surgical Robotic System
SS Innovations has announced that its SSi Mantra surgical robotic system has successfully completed over 10,500 surgeries, including various specialties. The company has trained approximately 2,100 physicians and expanded its presence globally with over 200 systems installed in 11 countries. The CEO highlighted the system's advanced technology and commitment to making robotic surgery accessible.
Read more →SSIISS Innovations Unveils Cutting-Edge Surgical Robotic Technologies at SMRSC 2026
SS Innovations announced the unveiling of several cutting-edge surgical robotic technologies at the SMRSC 2026 conference held in New Delhi. Key innovations include the SSi Vimana Aero, a drone-assisted surgical system for battlefield injuries, the SSi Avtara humanoid surgical platform, and the SSi Operion mobile operating room. These technologies aim to enhance accessibility and efficiency in surgical procedures across diverse environments. Furthermore, the conference saw a significant increase in attendance, supporting the growing interest in robotic surgery innovations.
Read more →SSIISS Innovations to Host SMRSC 2026 in New Delhi, India from April 9-11, 2026
SS Innovations will host the Global Multi-Specialty Robotic Surgery Conference (SMRSC 2026) from April 9-11, 2026, in New Delhi, India. This event aims to gather leading surgeons and innovative thinkers to discuss advancements in robotic and minimally invasive surgery. Attendance is expected to exceed previous conferences, with over 1,400 participants anticipated. The conference will showcase live procedures and new technologies to enhance surgical care and access.
Read more →SSIISS Innovations Expands Global Opportunity with Regulatory Approval of the SSi Mantra Surgical Robotic System in Colombia, Oman, Sri Lanka and Kenya
SS Innovations has received regulatory approval for its SSi Mantra surgical robotic system in Colombia, Oman, Sri Lanka, and Kenya. This approval enhances the company's position in underpenetrated markets, promoting affordable robotic surgery. The SSi Mantra has already been approved in eleven countries, with a significant number of surgeries performed, including specialized procedures.
Read more →SSII▲ +7.2%on this news
SS Innovations' SSi Mantra Surgical Robotic System Approved for Telesurgeries in Indonesia and the Philippines
SS Innovations announced that its SSi Mantra Surgical Robotic System has received approval for telesurgeries in Indonesia and the Philippines. The company has also surpassed the milestone of 150 successful telesurgeries, primarily conducted in India. The SSi Mantra enhances surgical capabilities by allowing remote operations and the sharing of expertise among physicians. Plans for further demonstration of the system's capabilities will occur at the upcoming Global Multi-Specialty Robotic Surgery Conference in New Delhi, where live telesurgeries will be performed.
Read more →SSII▼ -5.6%on this news
SS Innovations Reports Fourth Quarter and Full Year 2025 Financial Results
SS Innovations International, Inc. (Nasdaq: SSII) reported impressive financial results for Q4 and the full year 2025, highlighting significant growth in the installations and procedures of their SSi Mantra surgical robotic system. The company has expanded its market presence, particularly in India, and is making strides towards entering the U.S. and European Union markets. Additionally, a successful private placement raised approximately $18.6 million to support its growth initiatives. Future growth is anticipated as the company aims to enhance access to robotic surgery worldwide.
Read more →SSII▲ +5.4%on this newsshared move
SS Innovations Announces Completion of an $18.6 Million Private Placement to Support Growth Initiatives
SS Innovations International, Inc. has successfully completed a private placement, raising approximately $18.6 million. The funds will be used for working capital and to advance growth initiatives, particularly in India and preparations for entry into U.S. and EU markets. The company anticipates FDA review of its surgical robotic system by mid-2026.
Read more →SSII▲ +10.8%on this news
SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025
SS Innovations International, Inc. announced preliminary unaudited revenue for Q4 and full year 2025, expecting significant growth driven by increased sales of its SSi Mantra surgical robotic system. The company reported a 158% increase in its cumulative installed base. CEO Dr. Sudhir Srivastava expressed optimism about regulatory reviews and the company's commitment to expanding access to robotic surgery globally.
Read more →SSIISS Innovations Appoints Milan Rao as Global Chief Operating Officer and Chief Financial Officer
SS Innovations International, Inc. has appointed Milan Rao as its Global Chief Operating Officer and Chief Financial Officer, succeeding Naveen Kumar Amar. This newly created role comes as part of the company's strategy to reinforce its leadership team as it aims to expand its innovative surgical robotic technologies globally. Rao brings over thirty years of experience in technology and healthcare sectors and will work closely with the executive leadership during the transition period to define growth strategies and optimize operations.
Read more →SSII▲ +6.5%on this newsshared move
SS Innovations Develops New Instruments to Advance Robotic Surgery in Large, Underserved Patient Segments, including Pediatric and Cardiac Markets
SS Innovations International, Inc. has announced the completion of five new 5-millimeter surgical instruments to support robotic surgeries in pediatric and cardiac markets. These instruments can significantly improve access to surgical care for children, specifically targeting the 1.7 billion children and adolescents lacking timely interventions. The company aims to make robotic surgery more accessible for these underserved populations, with a focus on enhancing surgical outcomes during complex procedures. With the SSi Mantra surgical robotic system, SS Innovations plans to expand their global reach and capabilities.
Read more →SSIISS Innovations Submits 510(k) Premarket Notification to the FDA for the Company’s SSi Mantra Surgical Robotic System
SS Innovations International, Inc. has submitted a 510(k) premarket notification to the FDA for its SSi Mantra surgical robotic system, covering multiple surgical specialties. The company aims to introduce this cost-efficient technology to the U.S. market, targeting underserved patient communities. The SSi Mantra has already seen significant use globally, with plans for EU certification in 2026.
Read more →SSIISS Innovations Announces Successful Completion of First Telesurgery Performed with the Company’s SSi Mantra Tele Surgeon Console
SS Innovations International, Inc. has successfully completed its first telesurgery using the SSi Mantra Tele Surgeon Console (TSC). This innovative console allows surgeons to perform procedures remotely, enhancing accessibility to surgical care. The TSC's compact design supports telesurgery from various settings, demonstrating its potential to revolutionize surgical practices.
Read more →SSIIWe Build Advanced, Affordable and Accessible Surgical Robotic Solutions SS Innovations International, Inc. Company Presentation November 2025 Nasdaq: SSII 2025 SS INNOVATIONS INTERNATIONAL, INC. 2 No Offering of Securiti
SS Innovations International, Inc. presented its vision to develop advanced, affordable, and accessible surgical robotic solutions. The company highlights its proprietary system, the SSi Mantra 3, alongside significant achievements in surgical procedures and installations. With a strong leadership team and plans for global expansion, the company reported robust revenue growth and an increasing mix of recurring revenues. However, there are forward-looking statements that involve known and unknown risks.
Read more →SSIISS Innovations Reports Third Quarter 2025 Financial Results
SS Innovations International, Inc. reported strong financial results for Q3 2025, highlighting significant revenue growth attributed to the SSi Mantra 3 surgical robotic system. The company has received regulatory approval in seven countries and is preparing for entry into the U.S. and EU markets. A recent human factors validation study at Johns Hopkins Hospital supports their upcoming FDA submission.
Read more →SSIISS Innovations to Participate in Upcoming Investor Conferences
SS Innovations International, Inc. has announced participation in two upcoming investor conferences: the UBS Global Healthcare Conference on November 11, 2025, and the Stifel 2025 Healthcare Conference on November 12, 2025. Company executives will be available for one-on-one meetings, and a live webcast of the Stifel presentation will be accessible on their website. The company aims to make robotic surgery more affordable and accessible globally.
Read more →SSII▼ -8.6%on this news
SS Innovations Provides U.S. Regulatory Update for the SSi Mantra Surgical Robotic System
SS Innovations announced the successful completion of a human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital. The company plans to submit a 510(k) premarket notification to the FDA in Q4 2025, aiming for potential market clearance in early 2026. This marks a significant step towards making robotic surgery more accessible.
Read more →About SS Innovations International Inc.
Headquarters405, 3RD FLOOR, ILABS INFO TECH CENTRE, GURUGRAM, 122016
BIOPHARMAWATCH ELITE PLUS
Trade the next SSII catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime